Go to the list of all blogs
published in Blogs
Jul 14, 2026
Oklo Inc. (OKLO) Stock Falls -20.3% Over 30 Days as AI Nuclear Enthusiasm Cools

Oklo Inc. (OKLO) Stock Falls -20.3% Over 30 Days as AI Nuclear Enthusiasm Cools

Key Takeaways

  • Oklo Inc. (OKLO) shares have fallen approximately 20.3% over the last 30 days, closing at $45.81 on July 13, 2026, down from $57.49 on June 12, 2026.
  • The stock has declined roughly 27.7% over the broader quarter, reflecting waning enthusiasm for pre-revenue advanced nuclear energy names tied to AI infrastructure demand.
  • Key headwinds include the absence of Nuclear Regulatory Commission (NRC) approval for the Aurora Powerhouse reactor design, ongoing cash burn, and share dilution concerns.
  • Broader sector weakness has also weighed on peers including NuScale Power (SMR) and NANO Nuclear Energy (NNE).
  • With a market cap of approximately $7.97 billion and no revenue, OKLO remains a high-risk, development-stage energy investment.
  • Analysts maintain a consensus price target of $88.63, implying significant potential upside, but regulatory and commercialization timelines remain uncertain.

Oklo Inc. (OKLO) Company Overview and Market Position

Oklo Inc. is a Santa Clara, California-based advanced nuclear technology company founded in 2013. The company is developing the Aurora Powerhouse, a compact fast-neutron fission reactor designed to produce between 15 and 75 megawatts of electricity. Unlike conventional nuclear plants, Oklo's reactors are intended for direct deployment at data centers, industrial sites, and remote off-grid locations, providing carbon-free baseload power without burdening traditional utility grids. The company is also commercializing nuclear fuel recycling and fuel fabrication technology capable of converting used nuclear fuel into usable material for its reactors. Oklo went public in May 2024 through a merger with AltC Acquisition Corp., a special purpose acquisition company. As a pre-revenue enterprise with no NRC-approved commercial reactor design, Oklo represents an early-stage bet on next-generation nuclear energy at a time of surging electricity demand from artificial intelligence infrastructure.

Oklo Inc. (OKLO) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 calendar days, OKLO shares have declined approximately 20.3%, falling from a closing price of $57.49 on June 12, 2026, to $45.81 on July 13, 2026. The stock briefly touched its 52-week low of $44.88 in late March 2026 and has struggled to sustain any meaningful recovery above the $60 level since early June. Trading volume has remained elevated throughout the sell-off, with several sessions exceeding 10 million shares exchanged, indicating active institutional repositioning. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The quarterly picture is equally challenging. From mid-April 2026, when shares closed at $63.35 on April 15, OKLO has shed approximately 27.7% of its value. This period encompasses a volatile range that saw the stock spike above $80 in early May before a persistent downward trend set in through June and into mid-July. The 50-day moving average has declined to roughly $61.54, while the 200-day moving average sits near $82.37, both well above the current share price and indicating sustained bearish momentum across multiple timeframes.

What Drove OKLO Stock Price in the Last 30 Days

Several converging factors contributed to OKLO's sharp 30-day decline. First, the broader "AI nuclear" trade has materially cooled. Stocks that surged in 2025 on expectations that data center electricity demand would drive a nuclear renaissance have faced a significant repricing. Oklo, which rode that narrative to a peak above $193 per share in 2025, has been among the most affected as investors reassess the timelines and execution risks inherent in bringing new reactor designs to market.

Second, Oklo's fundamental profile remains speculative. The company generates no revenue, its Aurora Powerhouse design has not received NRC approval, and free cash flow burn reached negative $154 million over the trailing twelve months. While the company held approximately $2.21 billion in cash at the end of the first quarter of 2026, providing multiple years of operating runway, the path to commercialization remains measured in years rather than quarters. Third, dilution remains a persistent overhang. Shares outstanding have more than doubled over recent years as the company raised capital through equity offerings, and the short interest ratio stood at 16.04% of float as of late June, reflecting meaningful bearish positioning.

What Drove OKLO Stock Performance Over the Last Quarter

The quarterly decline extends beyond short-term sentiment shifts. The first half of 2026 saw Oklo shares lose roughly 27% of their value, according to market data. Several structural factors have reshaped investor perception over this period. The nuclear energy sector broadly has experienced a valuation reset as the initial euphoria surrounding AI-driven power demand gave way to more sober assessments of regulatory hurdles, construction timelines, and financing requirements. Competitors such as NuScale Power (SMR) have declined roughly 27% year-to-date, while NANO Nuclear Energy (NNE) has fared slightly better but remains in negative territory.

For Oklo specifically, analysts have revised loss estimates lower for both 2026 and 2027, reflecting expectations of continued investment in first-of-a-kind nuclear assets, fuel facilities, and regulatory work. The stock's price-to-book ratio has compressed from over 35 times at its peak to approximately 3.2 times, a dramatic valuation reset driven by declining share prices and growing book value from cash reserves. While this compression may make the stock appear less stretched by historical standards, it also underscores that the premium once assigned to Oklo's growth narrative has largely evaporated.

OKLO Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, the most critical catalyst for OKLO will be progress on NRC regulatory approval for the Aurora Powerhouse reactor design. Any milestone related to licensing, design certification, or construction permitting could materially shift sentiment. The company's next earnings report, anticipated around August 10, 2026, will provide updates on cash burn, partnership developments, and regulatory timelines. Investors should also monitor broader macroeconomic conditions, including interest rate policy and energy sector capital flows, which influence risk appetite for pre-revenue technology companies. Competitive developments from peers, changes in AI infrastructure investment trends, and any federal policy shifts related to advanced nuclear energy will also play a significant role. With short interest at elevated levels and a volatile trading history, OKLO remains susceptible to outsized moves in both directions.

Trending AI Robots

In my own research process, I frequently review Tickeron's Trending AI Robots page. It offers a curated selection of top-performing AI-powered trading bots from a universe of hundreds of bots trading thousands of tickers. These bots employ diverse strategies, operate across various timeframes, and are evaluated based on rigorous performance metrics. Only the most relevant and consistently strong-performing bots are featured, helping users identify strategies that align with their trading objectives. Whether seeking short-term momentum plays or longer-duration tactical approaches, exploring the Trending AI Robots can offer valuable insights into how algorithmic strategies are navigating today's market conditions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OKLO
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry ElectricUtilities

Profile
Details
Industry
N/A
Address
3190 Coronado Drive
Phone
N/A
Employees
N/A
Web
https://www.oklo.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Oklo Inc. (OKLO) Stock Falls -20.3% Over 30 Days as AI Nuclear Enthusiasm Cools